These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38022413)

  • 21. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
    Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
    Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of hyponatraemia and renal function in type 1 cardiorenal syndrome.
    Liang W; He X; Xue R; Wei F; Dong B; Wu Z; Owusu-Agyeman M; Wu Y; Zhou Y; Dong Y; Liu C
    Eur J Clin Invest; 2020 Sep; 50(9):e13269. PubMed ID: 32415981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome.
    Jungbauer CG; Birner C; Jung B; Buchner S; Lubnow M; von Bary C; Endemann D; Banas B; Mack M; Böger CA; Riegger G; Luchner A
    Eur J Heart Fail; 2011 Oct; 13(10):1104-10. PubMed ID: 21846754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography.
    Mavrakanas TA; Khattak A; Singh K; Charytan DM
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1624-1633. PubMed ID: 28801528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients.
    Iacoviello M; Aspromonte N; Leone M; Paradies V; Antoncecchi V; Valle R; Caldarola P; Ciccone MM; Gesualdo L; Serio FD
    Res Cardiovasc Med; 2016 Feb; 5(1):e28952. PubMed ID: 26870715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis.
    Medvedeva EA; Berezin II; Surkova EA; Yaranov DM; Shchukin YV
    Minerva Cardioangiol; 2016 Dec; 64(6):595-602. PubMed ID: 27119370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population.
    Tran SK; Ngo TH; Lai TT; Truong GK; Tran KDD; Vo PM; Nguyen PT; Nguyen PH; Nguyen TT; Nguyen OTK; Nguyen T; Nguyen KT; Tran HD
    Healthcare (Basel); 2023 Jan; 11(2):. PubMed ID: 36673621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiorenal syndrome as predictor of in-hospital mortality in ST-segment elevation myocardial infarction.
    Rodríguez-Jiménez AE; Negrín-Valdés T; Cruz-Inerarity H; Machural-de la Torre PJ
    Clin Investig Arterioscler; 2018; 30(4):163-169. PubMed ID: 29599092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure.
    Clementy N; Garcia B; André C; Bisson A; Benhenda N; Pierre B; Bernard A; Fauchier L; Piver E; Babuty D
    PLoS One; 2018; 13(8):e0201517. PubMed ID: 30067817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute decompensated heart failure and the cardiorenal syndrome.
    Liang KV; Williams AW; Greene EL; Redfield MM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S75-88. PubMed ID: 18158481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome.
    Melenovsky V; Cervenka L; Viklicky O; Franekova J; Havlenova T; Behounek M; Chmel M; Petrak J
    Kidney Blood Press Res; 2018; 43(5):1437-1450. PubMed ID: 30235455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
    Zhang MJ; Gu Y; Wang H; Zhu PF; Liu XY; Wu J
    Eur Rev Med Pharmacol Sci; 2016; 20(2):345-54. PubMed ID: 26875907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
    Ilges DT; Dermody ML; Blankenship C; Mansfield V; Van Tuyl JS
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):611-618. PubMed ID: 34138673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CRAS-EAHFE study: Characteristics and prognosis of acute heart failure episodes with cardiorenal-anaemia syndrome at the emergency department.
    Llauger L; Jacob J; Herrero-Puente P; Aguirre A; Suñén-Cuquerella G; Corominas-Lasalle G; Llorens P; Martín-Sánchez FJ; Gil V; Roset A; Ruibal JC; Pérez-Durá MJ; Juan-Gómez MÁ; Garrido JM; Richard F; Lucas-Imbernon FJ; Alonso H; Tost J; Gil C; Miró Ò;
    Eur Heart J Acute Cardiovasc Care; 2020 Aug; 9(5):406-418. PubMed ID: 32403935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of tanshinone II A inhibiting myocardial remodeling by Galectin-3].
    Zhang M; Cheng K; Yu L; Wu W; Wang Y; Chen Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jun; 34(6):640-645. PubMed ID: 35924522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators.
    Makimoto H; Müller P; Denise K; Clasen L; Lin T; Angendohr S; Schmidt J; Brinkmeyer C; Kelm M; Bejinariu A
    Intern Med; 2022; 61(7):969-977. PubMed ID: 35370254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction.
    Kanukurti J; Mohammed N; Sreedevi NN; Khan SA; Baba KSSS; Bhaskar MV; Satish OS; Naushad SM; Mohan IK
    J Lab Physicians; 2020 Aug; 12(2):126-132. PubMed ID: 32905127
    [No Abstract]   [Full Text] [Related]  

  • 40. Prognostic value of galectin-3 in adults with congenital heart disease.
    Baggen VJM; van den Bosch AE; Eindhoven JA; Menting ME; Witsenburg M; Cuypers JAAE; Boersma E; Roos-Hesselink JW
    Heart; 2018 Mar; 104(5):394-400. PubMed ID: 28942393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.